ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: By targeting ABL and BCR-ABL fusion proteins, NGP-21 holds promise in treating diseases associated with these aberrant proteins such as Chronic Myeloid Leukemia (CML).